Contact
Lena Rossignol
Email
+32 (0) 490 08 31 59
Enodia Therapeutics is a French-Belgian biotechnology company founded in 2025, originating from pioneering research conducted at Institut Pasteur and supported by the Argobio venture studio. Operating across Paris and Liège, Enodia develops a new generation of small-molecule therapeutics designed to control the production of disease-driving proteins at their source.
Its innovative approach is based on the selective modulation of Sec61, opening new possibilities to target proteins and disease mechanisms that remain difficult to address with conventional therapeutic strategies.
Enodia is currently advancing a growing preclinical pipeline across inflammation, immunology and oncology, with additional opportunities in virology.
Following a €20.7 million Seed financing round in early 2026, Enodia is entering a new phase of growth and expanding its scientific teams in Paris and Liège.
Joining Enodia means becoming part of a fast-growing biotech, working at the forefront of science and drug discovery, and contributing directly to the development of a novel therapeutic approach.
Enodia Therapeutics is looking for a resourceful and curious Engineer II to play an active role in our discovery and preclinical programs.
The successful candidate will contribute to the generation and analysis of high-quality experimental data to advance our understanding of target biology, drug mechanisms of action and selective Sec61 inhibition. The role will involve performing and optimizing cell-based, biochemical and molecular biology assays and contributing to the implementation of new experimental approaches.
Working closely with scientists and interdisciplinary project teams, the Engineer II will help translate experimental results into actionable insights, support project decision-making and contribute to the advancement of Enodia’s growing pipeline.
Your application will be handled in strict confidence, in accordance with GDPR. PaHRtners promotes diversity, equity and inclusion.